Packages (Simulation)
Reagent Preparation
Image (I)
-
Results demonstration
Image (II)
-
Typical Standard Curve
Quality Guarantee
Instruction Manual
Certificate
Multiplex Assay Kit for Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay)
GPATC7; GPATCH7; VG5Q; Angiogenic factor VG5Q; G patch domain-containing protein 7; Vasculogenesis gene on 5q protein
(Note: Up to 8-plex in one testing reaction)
- Product No.LML178Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample TypeSerum, plasma, tissue homogenates and other biological fluids.
- Test MethodDouble-antibody Sandwich
- Assay Length3.5h
- Detection Range0.01-10ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.003 ng/mL.
- DownloadInstruction Manual
- UOM 8Plex 7Plex 6Plex 5Plex 4Plex 3Plex 2Plex1Plex
- FOB
US$ 480
US$ 499
US$ 527
US$ 564
US$ 601
US$ 656
US$ 739
US$ 924
Add to Price Calculator
Result
For more details, please contact local distributors!
Specificity
This assay has high sensitivity and excellent specificity for detection of Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 87-105 | 98 |
| EDTA plasma(n=5) | 79-104 | 83 |
| heparin plasma(n=5) | 90-99 | 94 |
| sodium citrate plasma(n=5) | 79-103 | 87 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 80-94% | 81-90% | 90-99% | 78-97% |
| EDTA plasma(n=5) | 98-105% | 83-97% | 97-105% | 96-103% |
| heparin plasma(n=5) | 92-99% | 93-105% | 86-93% | 78-89% |
| sodium citrate plasma(n=5) | 90-98% | 98-105% | 89-103% | 97-104% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:AGGF1) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
GIVEAWAYS
INCREMENT SERVICES
| Magazine | Citations |
| Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease | Role of microRNA-27a in down-regulation of angiogenic factor AGGF1 under hypoxia associated with high-grade bladder urothelial carcinoma Pubmed:24462738 |
| Cancer Management and Research | IL-17 induces macrophages to M2-like phenotype via NF-κB Pubmed: 30323677 |
| Cellular Physiology and Biochemistry | Sinoporphyrin Sodium-Mediated Sonodynamic Therapy Inhibits RIP3 Expression and Induces Apoptosis in the H446 Small Cell Lung Cancer Cell Line Pubmed: 30562734 |